Organigram (OGI) Competitors $1.34 -0.01 (-0.74%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.02 (+1.87%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGI vs. AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, ABUS, AKBA, ZYBT, and EOLSShould you be buying Organigram stock or one of its competitors? The main competitors of Organigram include ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Organigram vs. ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology Evolus ArriVent BioPharma (NASDAQ:AVBP) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation. Which has better valuation & earnings, AVBP or OGI? Organigram has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$3.77-5.43Organigram$194.09M0.92-$33.39M$0.1013.40 Does the MarketBeat Community believe in AVBP or OGI? Organigram received 175 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 70.71% of users gave Organigram an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes23100.00% Underperform VotesNo VotesOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Does the media refer more to AVBP or OGI? In the previous week, ArriVent BioPharma had 12 more articles in the media than Organigram. MarketBeat recorded 19 mentions for ArriVent BioPharma and 7 mentions for Organigram. ArriVent BioPharma's average media sentiment score of 0.61 beat Organigram's score of 0.49 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Organigram 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, AVBP or OGI? ArriVent BioPharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Do analysts recommend AVBP or OGI? ArriVent BioPharma currently has a consensus price target of $39.29, indicating a potential upside of 91.92%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe ArriVent BioPharma is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Organigram 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AVBP or OGI more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Organigram's net margin of -31.69%. Organigram's return on equity of -8.59% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Organigram -31.69%-8.59%-6.54% Do insiders and institutionals hold more shares of AVBP or OGI? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryArriVent BioPharma and Organigram tied by winning 9 of the 18 factors compared between the two stocks. Get Organigram News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.34M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-3.538.9226.8419.71Price / Sales0.92250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.736.466.794.50Net Income-$33.39M$143.98M$3.23B$248.18M7 Day Performance9.84%3.04%4.07%1.14%1 Month Performance34.00%7.44%12.52%15.20%1 Year Performance-30.21%-2.46%16.83%6.56% Organigram Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram0.2552 of 5 stars$1.34-0.7%N/A-32.2%$179.34M$194.09M-3.53860AVBPArriVent BioPharma1.0085 of 5 stars$19.99-0.8%$39.00+95.1%+6.5%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.6014 of 5 stars$6.70+1.5%$17.56+162.1%+128.6%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.653 of 5 stars$9.81-2.2%$30.00+206.0%+11.5%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9033 of 5 stars$6.58+2.0%$30.57+364.6%-58.8%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2703 of 5 stars$20.08+2.5%$54.33+170.6%-24.9%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4368 of 5 stars$1.93+10.3%$14.80+666.8%-81.5%$644.49M$212.68M-1.30500Trending NewsGap DownHigh Trading VolumeABUSArbutus Biopharma1.8646 of 5 stars$3.35+3.7%$5.50+64.2%+4.6%$641.46M$6.17M-7.7990Earnings ReportGap UpAKBAAkebia Therapeutics4.225 of 5 stars$2.43-4.7%$6.63+172.6%+153.9%$636.14M$160.18M-10.56430High Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278Gap DownEOLSEvolus3.5772 of 5 stars$9.98+1.8%$23.75+138.0%-25.8%$631.87M$266.27M-10.97170Gap UpHigh Trading Volume Related Companies and Tools Related Companies AVBP Competitors TRVI Competitors PHAR Competitors DAWN Competitors DNTH Competitors IOVA Competitors ABUS Competitors AKBA Competitors ZYBT Competitors EOLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OGI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGI Stock Free OGI Stock Alerts